Theseus Pharmaceuticals is developing what it calls “pan-variant” kinase inhibitors in the hopes of outsmarting tumors by anticipating the range of kinases that may drive their spread and growth as they change.

Regeneron has agreed to supply Elicio Therapeutics with the drug Libtayo for clinical trials of its candidate cancer vaccine, ELI-002.

Recce is developing new classes of anti-infectives that hold the potential to resolve multidrug-resistant in­fections safely and effectively.

MindMed tapped Greenway as CFO on Monday, as CEO Robert Barrow guides the company through what he called “an exciting point in our growth.” The New York-based psychedelics company was the second to ever go public on an American exchange, behind Compass Pathways. And this year, Barrow’s lining up “numerous near-term milestones ahead across our pipeline.”

Jeff Cleland, PhD, CEO of Ashvattha, discusses safety data for an at-home subcutaneous injection option being developed for wet AMD and DME. The anti-VEGF candidate will enter a Phase 2 study later this year.

MindMed (NASDAQ:MNMD; NEO:MMED) is advancing a pipeline of psychedelic and next generation drug candidates to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology.

Umoja Biopharma will pair its so-called VivoVec particles with Lupagen’s Side CAR-T delivery system to target certain cancers, the companies said Monday.

Cerevance is targeting these fluctuations with a planned Phase II/III trial of its investigational compound CVN424, CMO Jordan Dubow says. The Boston-based biotech plans to initiate the study in the first quarter of 2023, testing CVN424 as an adjunctive therapy to levodopa, he adds.